St. Jude’s research highlighted at American Society of Clinical Oncology annual meeting

Learn about best practices and hear insights from oncologists, psychologists, scientists and others at St. Jude Children’s Research Hospital at the annual gathering of clinical oncology experts.

MEMPHIS, Tenn., May 31, 2022 /PRNewswire/ — Professionals from St. Jude Children’s Research Hospital will share their original research and expertise at the annual meeting of the American Society of Clinical Oncology (ASCO). The meeting will take place June 4-8, at McCormick Place in Chicago and include online lectures.

ASCO is the premier professional society for clinical oncology, representing nearly 45,000 people dedicated to cancer care.

ASCO Pediatric Oncology Award 2022

Amar Gajjar, MD, Department of Pediatric Medicine and Chair of the Department of Oncology, will receive the 2022 ASCO Pediatric Oncology Award. Gajjar received this year’s award for his work leading clinical trials developing new treatments for pediatric brain tumours. He will accept the award in person and will have a pre-recorded lecture available on demand, online. He is the seventh St. Jude Investigator to receive this honor. The prize giving is 9:30 a.m. CST, Saturday June 4 in hall N B1.

A new approach to neuroblastoma

Neuroblastoma is a rare childhood cancer that develops in neuroblasts, cells that turn into nerve cells. High-risk neuroblastoma has a survival rate of about 50%. In a pilot study, St. Jude researchers worked with the clinical trial organization Children’s Oncology Group. Together, they found that adding the chemoimmunotherapy dinutuximab to the treatment of pediatric patients with relapsed or refractory neuroblastoma produced an 86.8% response rate.

Sara Federico, MD, Department of Oncology at St. Jude, will present the findings in his talk “A Pilot Induction Regimen Incorporating Dinutuximab and Sargramostim for the Treatment of Newly Diagnosed High-risk Neuroblastoma: A Report from the Children’s Oncology Group.” Federico’s talk complements other research on high-risk neuroblastoma survival disparities that is being presented at the meeting. Federico’s speech is 3:36 p.m. CST, Monday, June 6in room S406, as part of the pediatric oncology session.

A global perspective

Two St. Jude researchers are included in the paid session, “Meet the Professors: Improving Childhood Cancer Outcomes Worldwide.” Carlos Rodriguez GalindoMD, St. Jude Chair in Global Pediatric Medicine, will present “Life in Wartime: SAFER Ukraine”. Catherine Lam MD, Global Pediatric Medicine, will present a report on “Improving Global Outcomes in Pediatric Oncology: The World Health Organization’s Global Initiative for Childhood Cancer”. The session starts at 4:45 p.m. CST, Saturday June 4in room E253b.

Educational session on medulloblastoma

Paul Northcott, Ph.D., St. Jude Department of Developmental Neurobiology, will present “The Genetics and Epigenetics of Medulloblastoma: Implications for Risk Stratification”. His lecture is part of the educational session “Medulloblastoma: Molecular Classification, Risk Stratification, and Therapeutic Implications”. It’s a 11:30 a.m. CST, Sunday June 5in room S504.

Beat Cancer Award

Three St. Jude researchers will receive ASCO Foundation Conquer Cancer Awards at the annual meeting. Dylan GraetzMD, Department of Global Pediatric Medicine, will receive a Career Development Fellowship, which provides three years of research funding to promising early career investigators developing their own clinical cancer research program. Caitlyn DuffyMD, Department of Oncology, and Marta Salek, MD, Department of Oncology, will both receive the Global Oncology Young Investigator Awards. This award funds early career researchers tackling global health needs.

Presentation of original research posters

St. Jude scientists will present original research on a variety of topics in poster sessions throughout the conference. The primary focus of these posters will be pediatric oncology, including post-treatment neurocognitive or cardiac function. The posters also evaluate new cancer therapies and link nutrition to treatment-induced disease.

St. Jude Children’s Research Hospital

St. Jude Children’s Research Hospital is at the forefront of how the world understands, treats, and cures childhood cancer and other life-threatening illnesses. It is the only comprehensive cancer center designated by the National Cancer Institute devoted solely to children. Treatments developed at St. Jude have helped increase the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude freely shares the breakthroughs it achieves, and every child saved at St. Jude means doctors and scientists around the world can use that knowledge to save thousands more children. To learn more, visit or follow St. Jude on social media at @stjuderesearch.

SOURCE St. Jude Children’s Research Hospital

About Terry Gongora

Check Also

Strata Oncology Senior Vice President of Clinical Development Kat Kwiatkowski to Participate in Two Panels at the Precision Medicine World Conference

Title: Removing Barriers to Biomarker Testing Through Collaboration Time: Tuesday, June 28 at 9:00 a.m. …